# Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL

> **NCT07494565** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 60 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma (DLBCL)
- CD5 Positive

## Interventions

- **DRUG:** Celecoxib Combined with R-CHOP
- **DRUG:** R-CHOP

## Key facts

- **NCT ID:** NCT07494565
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-05
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07494565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07494565, "Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07494565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*